Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunityArvin Iracheta‐Vellve, Robert T. Manguso, Kathleen A. McGuire et al.|Cancer Research|2022Cited by 8
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7
1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activityKathleen A. McGuire, Philip R. Kym, Christina K. Baumgartner et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1
Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunityHakimeh Ebrahimi-Nik, Robert T. Manguso, Arvin Iracheta‐Vellve et al.|Cancer Immunology Research|2022Cited by 0
1037P Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484Hakimeh Ebrahimi-Nik, Robert T. Manguso, Christina K. Baumgartner et al.|Annals of Oncology|2024Cited by 0